CME Group frames demand for perpetual futures as centered on institutional use-cases and hedging fit, concluding that the strongest signal comes from institutional participation rather than headline-driven chatter. It argues perpetuals fail hedging requirements, incur higher costs, provide limited protections, and could pose systemic risks, with crypto futures growth reinforcing CME’s emphasis on established risk-management tools.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
How did CME measure and interpret customer demand signals regarding perpetual futures across different asset classes, and what specific objections did institutional participants raise about risk management, cost, and protections?
CME’s executives framed perpetual futures as outside the needs of their dominant customer base, emphasizing that 94% of volume in the first half of 2026 originated from institutional customers.1 Based on this, management interpreted institutional engagement (not just industry headlines) as the key metric for whether perpetuals would fit CME’s role as a risk-management venue.2
On the crypto side, CME pointed to growth in its futures complex and compared those outcomes to a specific crypto perp product introduction:
CME’s interpretation: despite perpetuals existing in crypto, CME’s futures demand still grew (it stated crypto perpetuals “are not new” and existed before CME’s crypto futures complex launched in 2017, and it said its crypto futures volume is up over sevenfold in the past three years).4
CME explicitly stated: “we have not heard demand from our customers for these products.”4 It further argued that CME’s futures filled a market need “not met by traditional crypto products, including perpetuals.”4
CME’s management argued that the type of demand that matters for institutional users is functional hedging:
Management then concluded that perpetuals “do not appeal to our core customers” and are “in no way substitutes for the institutional hedging tools that these customers rely on.”1
CME acknowledged perpetuals may appeal to some retail traders seeking high leverage,1 but interpreted this as not a relevant signal for CME’s institutional-driven franchise—especially because retail-focused products come with “limited investor protections” and “heightened market risk,” particularly for retail participants.1
CME management gave detailed objections—some direct (institutions “do not want this product”) and others framed as structural shortcomings of perpetuals.
CME said institutions in energy/commercial derivatives explicitly reject perpetual risk structures:
Separately, CME argued perpetuals miss key hedging requirements for institutions:
CME claimed that, when considering both trading economics:
It also made a cost-comparison specific point on crypto perp structures:
CME stated perpetuals provide:
CME raised a regulatory/market-structure concern tied to design complexity and understanding:
CME explicitly framed the objections as a mismatch with institutional risk transfer:
CME acknowledged perpetuals are part of the broader crypto-native ecosystem but argued CME’s measured demand signals show institutional and overall market risk management still favors CME futures:
CME’s strongest institutional objection narrative came from energy/commerce-related conversations:
CME emphasized systemic and transparency concerns and reiterated the institutional/protection mismatch:
CME said it measured demand mainly through institutional participation and customer-confirmed use-cases, and it argued that market proxies (open interest and trading volumes in its futures complex) show stronger risk-management demand than perpetuals provide—especially in crypto.134 It interpreted persistent perpetual headlines as insufficient evidence because institutional customers reject perpetual risk management mechanics, citing lack of hedging fit (no price/time certainty; funding-rate/auto-liquidation structure), materially higher total costs (fees + funding; “orders of magnitude” and “sevenfold” execution-cost comparisons), and limited protections plus systemic-risk concerns in equities.1562
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
CME Group detailed a new, financially settled structure for Single Stock Futures designed to be more accessible and plug-and-play for global distribution, differentiating it from prior attempts. Confidence in a Monday launch is anchored in active partner testing (over 35 retail partners targeting day-one readiness) and broad liquidity-provider readiness, backed by favorable equity-market momentum signaling rising demand for risk management tools.
Sources used
Research questionFor Single Stock futures next week, what pricing/contract structure details did management cite as differentiators versus the prior attempt, and how did distribution partner readiness factor into CME’s confidence in timing?
Answer outline
CME Group's Q1 2026 results showcase exceptional market activity, with record revenues driven by broad-based trading volume and strategic fee structures.
Sources used
Research questionHow did CME Group's record revenue and adjusted operating results in Q1 2026 reflect its market performance?
Answer outline
CME Group's impressive first quarter of 2026 was driven by record trading volumes, broad market participation, and strong revenue growth, reflecting robust market performance.
Sources used
Research questionHow did CME Group's record revenue and adjusted operating results in Q1 2026 reflect its market performance?
Answer outline
CME Group's Q1 2026 record volume reflects robust demand across multiple asset classes and sustained market participation, backed by rising open interest and fee growth, indicating a resilient and expanding market environment.
Sources used
Research questionWhat does the record volume in Q1 2026 indicate about CME Group's demand and backlog signals?
Answer outline
CME Group's Q1 2026 results showcase record-breaking revenue driven by unprecedented market activity and broad asset class participation, highlighting its strong market position.
Sources used
Research questionHow did CME Group's record revenue and adjusted operating results in Q1 2026 reflect its market performance?
Answer outline
CME Group's Q1 2026 results highlight record trading volume and rising open interest, indicating strong demand and sustained activity across all asset classes.
Sources used
Research questionWhat does the record volume in Q1 2026 indicate about CME Group's demand and backlog signals?
Answer outline
CME Group's record Q1 2026 volume highlights robust, widespread demand for risk management services, supported by sustained open interest and strategic volume tiering mechanisms.
Sources used
Research questionWhat does the record volume in Q1 2026 indicate about CME Group's demand and backlog signals?
Answer outline
CME Group’s Q1 2026 financial results showcased exceptional market activity, leading to record revenue and profit margins, driven by increased trading volumes and broad-based market participation.
Sources used
Research questionHow did CME Group's record revenue and adjusted operating results in Q1 2026 reflect its market performance?
Answer outline
CME Group's record Q1 2026 volume underscores strong broad-based demand across all asset classes, with evidence of durable positioning reflected in open interest growth and increased fee generation.
Sources used
Research questionWhat does the record volume in Q1 2026 indicate about CME Group's demand and backlog signals?
Answer outline
CME Group's Q1 2026 results reveal record trading volume and rising open interest across all asset classes, indicating strong current demand and sustainable market activity.
Sources used
Research questionWhat does the record volume in Q1 2026 indicate about CME Group's demand and backlog signals?
Answer outline
CME Group's Q1 2026 results showcase record revenue driven by exceptional market activity, broad asset class participation, and strong market data demand, reflecting robust financial health and market confidence.
Sources used
Research questionHow did CME Group's record revenue and adjusted operating results in Q1 2026 reflect its market performance?
Answer outline
The OPUS-1 Phase III trial by Vaxcyte details statistical power assumptions and a noninferiority margin framework designed to demonstrate vaccine efficacy compared to Prevnar 20 and Capvaxive. Regulatory insight emphasizes flexible criteria favoring overall success rather than strict per-serotype noninferiority.
Sources used
Research questionCan you quantify the statistical power assumptions and noninferiority margins used for OPUS-1 versus each comparator?
Answer outline